Group 1 - The pharmaceutical and biotech industry is showing signs of marginal improvement in H1 2025, with a notable recovery in the pharmaceutical and CXO sectors [1] - Innovative drugs have become a key focus for the pharmaceutical sector, with revenue and net profit growth rates of 6.9% and 56.1% respectively, and a gross margin increase to 77.7% [1] - Overall profitability in the pharmaceutical industry has slightly improved, with a decrease in R&D investment and a focus on innovation and global expansion as critical growth drivers [1] Group 2 - China's innovative drugs are entering a phase of realization, with significant R&D progress that is not affected by trade frictions, expected to remain a main investment theme for the pharmaceutical sector in 2025 [1] - The Guotai Innovation Drug ETF (589720) focuses on innovative drug companies listed on the STAR Market, tracking an index of 30 representative high-quality companies, primarily in high-growth biotech [1] - Since the "924 market" last year, the STAR Market innovative drug index has outperformed major Hong Kong innovative drug indices, with respective gains of 75%, 70%, and 70% during the market rebound from September 24, 2024, to June 30, 2025 [1]
20cm速递丨科创创新药ETF（589720）盘中领涨超4%，去年“924行情”以来跑赢主要港股创新药指数，机构称创新药已成医药板块重要主线
Mei Ri Jing Ji Xin Wen·2025-09-01 05:01